AG
ARRY

Artal Group’s Array Biopharma Inc ARRY Stock Holding History

Artal Group’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-500,000
Closed -$6.4M – 145
2017
Q4 		$6.4M Sell
500,000
-500,000
-50% -$5.69M 0.1% 61
2017
Q3 		$12.3M Buy
1,000,000
+500,000
+100% +$4.64M 0.21% 35
2017
Q2 		$4.18M Buy
+500,000
New +$4.09M 0.07% 71
2016
Q1 		– Sell
-300,000
Closed -$1.27M – 86
2015
Q4 		$1.27M Hold
300,000
– – 0.02% 77
2015
Q3 		$1.37M Hold
300,000
– – 0.03% 72
2015
Q2 		$2.16M Buy
+300,000
New +$2.21M 0.09% 65
2015
Q1 		– Sell
-310,000
Closed -$1.47M – 97
2014
Q4 		$1.47M Buy
+310,000
New +$1.23M 0.05% 84

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group's ARRY Position: Q2 2019 in Review

Artal Group sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 2,000,000 shares — an estimated $48.8M sold.

Artal Group first reported a position in ARRY in Q2 2013 and held it in 24 quarters. The position peaked at $48.8M in Q1 2019. 319 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Artal Group reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Artal Group sold 2,000,000 Array Biopharma Inc shares in Q2 2019, an estimated $48.8M.
  • Artal Group first reported a position in Array Biopharma Inc in Q2 2013 and held it in 24 quarters.
  • Artal Group's Array Biopharma Inc position peaked at $48.8M in Q1 2019.
  • 319 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Artal Group's 13F filing for Q2 2019, filed 9 Aug 2019.